Profile data is unavailable for this security.

About the company

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

  • Revenue in USD (TTM)53.66bn
  • Net income in USD11.84bn
  • Incorporated1942
  • Employees92.40k
  • Location
    Pfizer Inc235 E 42ND STNEW YORK 10017-5703United StatesUSA
  • Phone+1 (212) 573-2323
  • Fax+1 (302) 655-5049
  • Websitehttps://www.pfizer.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PFE:NYQ since
Array Biopharma IncDeal completed17 Jun 201917 Jun 2019Deal completed-14.73%11.37bn
Therachon AG (Now 4j8824)Deal completed08 May 201908 May 2019Deal completed-10.70%810.00m
Data delayed at least 15 minutes, as of Oct 18 2019 23:30 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Eli Lilly And Co23.23bn4.34bn104.88bn38.68k24.7037.7418.394.524.407.9723.492.880.57341.484.46600,553.3010.716.4815.509.0076.6774.0118.6811.690.866622.230.846787.087.361.2299.27-6.1722.522.80
AbbVie Inc32.62bn4.18bn113.07bn30.00k27.55--18.563.472.782.7221.88-5.790.54934.255.791,087,467.007.089.309.9412.1277.3977.2412.8918.820.77956.261.3083.7616.0811.751.066.835.3817.54
Amgen, Inc.23.56bn7.96bn121.57bn21.50k16.0611.3112.225.1612.6312.6337.3117.930.37091.356.451,095,907.0012.539.9615.1211.4282.1781.1533.7732.602.6014.120.739340.323.934.923.9010.561.2722.94
Pfizer Inc.53.66bn11.84bn201.66bn92.40k17.833.3911.083.762.052.189.2510.770.33411.315.46580,703.407.405.419.276.5080.1179.4222.1417.731.2119.670.437981.632.100.7874-13.10-1.888.437.21
Merck & Co., Inc.44.37bn9.72bn216.81bn69.00k22.837.8715.914.893.713.5716.9010.770.5252.335.82643,014.5011.366.6814.718.3571.0966.2121.6315.620.918745.990.489481.415.41-0.802629.698.1311.062.96
Data as of Oct 18 2019. Currency figures normalised to Pfizer Inc's reporting currency: US Dollar USD

Institutional shareholders

30.44%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 2019437.37m7.91%
SSgA Funds Management, Inc.as of 30 Jun 2019293.39m5.30%
BlackRock Fund Advisorsas of 30 Jun 2019267.56m4.84%
Capital Research & Management Co. (World Investors)as of 30 Jun 2019161.99m2.93%
Wellington Management Co. LLPas of 30 Jun 2019134.71m2.44%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 201993.39m1.69%
Geode Capital Management LLCas of 30 Jun 201985.08m1.54%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 201976.44m1.38%
JPMorgan Investment Management, Inc.as of 30 Jun 201974.06m1.34%
State Farm Investment Management Corp.as of 30 Jun 201959.68m1.08%
More ▼
Data from 30 Jun 2019 - 30 Jun 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.